SITE007-0122

SITE007 (JPN) › SITE007-0122

SITE007-0122

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2026-01-20

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-31 (study day 182); relationship: not assessed

moderate assessed

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-01-20 (study day 171); relationship: not assessed

moderate assessed

Grade 3 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 168); relationship: NOT RELATED

severe assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-01-16 (study day 167); relationship: NOT RELATED

moderate assessed

Grade 1 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-11-25 (study day 115); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.